InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,868.06
(
0.46%
)
US TECH 100
19,795.20
(
0.74%
)
Dow Jones
43,290.86
(
0.12%
)
Brent Oil
72.83
(
-1.79%
)
Bitcoin
68,949.98
(
2.27%
)
Post# of 253398
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 840
Posts 120586
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Double_Bagel post# 176983

Saturday, 04/19/2014 5:52:39 PM

Saturday, April 19, 2014 5:52:39 PM

Post# of 253398
True to form: Teva, in announcing the unfavorable USSC ruling on an injunction (#msg-100802686), sneaks in a little propaganda vis-à-vis Copaxone characterization:

http://finance.yahoo.com/news/teva-announces-supreme-court-denial-134000735.html

The inability to fully characterize the active ingredients of the product leads many experts to believe that the only way to ensure the safety, efficacy and immunogenicity of any purported generic version of COPAXONE would be through full-scale, placebo-controlled clinical trials with measured clinical endpoints (such as relapse rate) in RRMS patients [emphasis added].

I wonder who those experts are, LOL.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up